Daiichi Sankyo teams up with US firm to develop biosimilars
Mainichi Daily News
Daiichi Sankyo will introduce relevant technology from Coherus BioSciences to develop biosimilar forms of etanercept for rheumatism treatment and rituximab for cancer treatment. The Japanese drugmaker will put them on sale in Japan, South Korea and ...
Daiichi Sankyo, Coherus partner to develop biosimilar candidatesPharmaceutical Business Review
Coherus launches with Daiichi Sankyo biosimilar pactPharma Times

all 6 news articles »